H
Hautarztpraxis Dr. Niesmann and Dr. Othlinghaus | Hautzentrum im Jahrhunderthaus
Research site
(Unclaimed)
Site insights
Top conditions
Top treatments
ABP 501
ABP 654
Humira®
Ritlecitinib
Data sourced from clinicaltrials.gov
Work at this site?
CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.
Active trials
2 of 5 total trials
The purpose of this study is to learn about the safety and effects of the study medicine ritlecitinib for the possible treatment of nonsegmental viti...
Enrolling
Stable Nonsegmental Vitiligo
Active Nonsegmental Vitiligo
Drug: Ritlecitinib
Drug: Placebo
This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.
Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab
Trial sponsors
Clinical trials
Research sites
Resources
Legal
© Copyright 2024 Veeva Systems